BENGALURU, Jan. 8 (Reuters) — Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
The company is targeting a valuation of up to $945.4 million in the IPO.
Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich
Jan 8 — Cancer drug developer Aktis Oncology priced its upsized U.S. initial public offering at $18 per share on Thursday, raising about $318 million. The company is targeting a valuation of up to $945.4 million in the IPO.
Reporting by Bipasha Dey in Bengaluru; Editing by Rashmi Aich